Leaps by Bayer
Profile, fund size and portfolio
Leaps by Bayer is the corporate venture arm of Bayer AG (pharmaceuticals and crop science). It was founded in 2015 and is based in Berlin, Germany. It invests from Seed to Series B in health, agriculture.
Every figure links to its source
Snapshot
Data behind this graphic
| Item | Value |
|---|---|
| Stage range | Seed to Series B |
| Sectors | Health, Agriculture |
| Geography | North America, Europe, Singapore and China |
| Offices | Berlin, Germany, Boston, United States, Basel, Switzerland, Bay Area, United States, St. Louis, United States |
Sources: S1 Leaps by Bayer approach (Wayback copy 2026; live site blocks bots); S7 Leaps by Bayer Annual Review 2025 (PDF).
Data behind this graphic
| Item | Companies | Share |
|---|---|---|
| Health | 42 | 65.6% |
| Agriculture | 22 | 34.4% |
A company can carry more than one tag
Sources: S5 Leaps portfolio, health (Wayback copy 2025-08-03; page data feed has status, first investment date, website).
Data behind this graphic
| Measure | Value | Unit | Kind | Source |
|---|---|---|---|---|
| Headline size | USD 2.1bn+ | Cumulative invested | Stated by the firm or its parent | S1 |
| Companies backed | 65+ | companies | Stated by the firm | S1 |
| Exits | 16 | exits | Stated by the firm | S5 |
| Companies on the firm's portfolio page | 64 | companies | Counted from the firm's own list | S5 |
Sources: S1 Leaps by Bayer approach (Wayback copy 2026; live site blocks bots); S5 Leaps portfolio, health (Wayback copy 2025-08-03; page data feed has status, first investment date, website).
Where it invests and who leads it
Geography
- Headquarters
- Berlin, Germany
- Offices
- Berlin, Germany
- Boston, United States
- Basel, Switzerland
- Bay Area, United States
- St. Louis, United States
Investment regionsS1S7
- North America
- Europe, Singapore and China
LeadersS4S2S3
- Juergen EckhardtEVP and Head of Leaps by BayerLinkedInFirm page
- Rakhshita DharHead of Health Venture Investments (Co-head of Health Venture Investments in 2026-07 Wayback copy)LinkedInFirm page
- Paimun AminiVP of Agriculture Venture InvestmentsLinkedInFirm page
- Brendan KellySenior Director of Health Venture InvestmentsFind on LinkedInFirm page
- Sara OlsonSenior Director of Agriculture Venture InvestmentsLinkedInFirm page
Key facts
| Fact | Value | Status | Source |
|---|---|---|---|
| Parent company | Bayer AG (XETRA: BAYN) | Single source | S9 |
| Parent industry | Pharmaceuticals and crop science | Single source | S9 |
| Founded | 2015 | Single source | S7 |
| Headquarters | Berlin, Germany | Single source | S2 |
| Status | Active | Single source | S9 |
| Capital source | Parent company only | Single source | S1 |
| Headline size | USD 2.1bn+ (Cumulative invested) | Single source | S1 |
| Companies backed | 65+ | Single source | S1 |
| Exits | 16 total | Single source | S5 |
| People on the team page | 18 | Single source | S2 |
| Stages | Seed, Series A, Series B | Single source | S1 |
Portfolio
The firm's portfolio page lists 64 companies: 48 active, 16 exited.S5
| Tag | Companies | Share |
|---|---|---|
| Active | 48 | 75% |
| Exited | 16 | 25% |
| Tag | Companies | Share |
|---|---|---|
| Health | 42 | 65.6% |
| Agriculture | 22 | 34.4% |
Every company on the Leaps by Bayer list
64 companies, as listed on the firm's own website: 48 active, 16 exited.S5 Read the firm's list.
Active 48
- 65Lab
- Ada Health
- Aferna Bio
- Affini-T Therapeutics
- AgBiome
- Amfora
- AMR Action Fund
- Andes
- Apollo Agriculture
- Atomwise
- Bloom Science
- Capstan Therapeutics
- Cellino
- ChrysaLabs
- CORXEL
- Deka Biosciences
- Dewpoint
- EarthOptics
- Edifice Health
- eGenesis
- Fork \u0026 Good
- FutuRx
- Gandeeva Therapeutics
- Grão Direto
- GRO Biosciences Inc.
- Guardian Agriculture
- Huma
- Immunitas Therapeutics
- Indapta Therapeutics
- Khloris Biosciences
- Kojin Therapeutics
- Mozart Therapeutics
- New Leaf Symbiotics
- Nextpoint Therapeutics
- NuCicer
- Nuvig Therapeutics
- Oerth Bio
- One Drop
- Pairwise
- Paratus Sciences
- Rantizo
- Recode Therapeutics
- Sound Agriculture
- Sudo Biosciences
- Triumvira Therapeutics
- Ukko
- Vesigen Therapeutics
- Woebot Health
Exited 16
- Arvinas
- Azitra
- BlueRock Therapeutics
- Boundless Bio
- Care/of
- Casebia Therapeutics
- Century Therapeutics
- Combyne
- CoverCress
- CRISPR Therapeutics
- Joyn Bio
- Metagenomi
- Pyxis Oncology
- Recursion
- Senti Bio
- Unfold
For founders
| Item | What the firm says | Source |
|---|---|---|
| Stages | Seed, Series A, Series B | S1 |
| Leads rounds | Yes. "Series B funding led by Leaps by Bayer" | S10 |
| Beyond capital | Active incubation: team members engage in company development, providing resources and helping steer the initial direction; Portfolio companies remain autonomous with respect to decision making | S1 |
| Contact form | leaps.bayer.com/contact | S12 |
Notable outcomes
IPOs and acquisitions of portfolio companies. Price shown only where published.
Recent rounds
| Date | Company | Round | Amount | Led by the firm | Source |
|---|---|---|---|---|---|
| 2026-07-14 | Sabanto | Series B | Not stated | S10 | |
| 2026-07-02 | Celea Therapeutics | Financing round (stage not stated in Reuters text) | USD 180M | S11 | |
| 2026-06-01 | SonoThera Therapeutics | Investment announced June 2026 (round not stated) | Not stated | S9 | |
| 2026-06-01 | Leaf, Inc. | Further investment announced June 2026 | Not stated | S9 |
Investments by year
History
- Leaps by Bayer founded; first investment in CRISPR Therapeutics and co-founded Casebia.S7
- Co-founded BlueRock Therapeutics.S7
- Invested in Century Therapeutics; BlueRock Therapeutics became part of Bayer.S7
- Century Therapeutics and Recursion listed on Nasdaq.S7
- Total invested passed USD 2 billion; first Chinese investment (CORXEL).S7
- Capstan Therapeutics acquired by AbbVie for USD 2.1 billion in cash.S7
- Led Sabanto Series B (14 Jul 2026); participated in Celea Therapeutics USD 180M financing (Reuters, 2 Jul 2026).S10
Where sources disagree
- Leaders.Fabio Pucci / Rakhshita Dhar title: Wayback 2026-07-07: Fabio Pucci and Rakhshita Dhar both Co-head of Health Venture Investments (S3) vs Live fetch 2026-10-02: Rakhshita Dhar Head of Health Venture Investments; Fabio Pucci not listed (S2). Team page changed between snapshots; Pucci LinkedIn link exists in the Wayback copy only.S3S2
Official pages
Read the firm's own pages for current information.
- Website leaps.bayer.com
- Portfolio leaps.bayer.com/companies/health
- LinkedIn company page www.linkedin.com/company/leapsbybayer
Sources
- S1Leaps by Bayer approach (Wayback copy 2026; live site blocks bots)Firm
- S2Leaps by Bayer team (live, via fetch tool)Firm
- S3Leaps by Bayer team page (Wayback copy 2026-07-07, with LinkedIn links)Firm
- S4Juergen Eckhardt profile (leaps.bayer.com)Firm
- S5Leaps portfolio, health (Wayback copy 2025-08-03; page data feed has status, first investment date, website)Firm
- S6Leaps portfolio, agriculture (Wayback copy)Firm
- S7Leaps by Bayer Annual Review 2025 (PDF)Firm
- S8Leaps by Bayer Annual Review 2023 (PDF)Firm
- S9Bayer Half-Year Financial Report Q2 2026: Leaps by BayerParent company
- S10Sabanto and Leaps by Bayer announce Series B (PR Newswire)Portfolio company
- S11Reuters via 740 The FAN: PureTech entity Celea raises $180 millionPress
- S12Leaps by Bayer contact (Wayback copy)Firm
- S13Leaps by Bayer on LinkedInFirm
- S14Leaps by Bayer news page (Wayback copy)Firm
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by Leaps by Bayer or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.